Evidence map›Paper›PMID 41169432›Full record

ArticleFrontiers in medicine2025

Burden of chronic obstructive pulmonary disease in China from 1990 to 2021: a population-based study.

Xuefang Wang, Jing Liu, Juan Li, Ling Zhang, Xiuqin Zeng, Ruijun Cai

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xuefang Wang *Department of Pharmacy, Shanghai General Hospital Jiuquan Hospital (The People's Hospital of Jiuquan), Jiuquan, Gansu, China.
Jing Liu *Department of Pharmacy, Shanghai General Hospital Jiuquan Hospital (The People's Hospital of Jiuquan), Jiuquan, Gansu, China.
Juan LiDepartment of Pharmacy, Shanghai General Hospital Jiuquan Hospital (The People's Hospital of Jiuquan), Jiuquan, Gansu, China.
Ling ZhangDepartment of Pharmacy, Shanghai General Hospital Jiuquan Hospital (The People's Hospital of Jiuquan), Jiuquan, Gansu, China.
Xiuqin ZengDepartment of Pharmacy, Shanghai General Hospital Jiuquan Hospital (The People's Hospital of Jiuquan), Jiuquan, Gansu, China.
Ruijun CaiDepartment of Pharmacy, Shanghai General Hospital Jiuquan Hospital (The People's Hospital of Jiuquan), Jiuquan, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is associated with high prevalence, disability, and mortality rates. As one of the most populous countries facing a significant burden of COPD, the extent of this burden in China remains inadequately defined. This study utilizes data from the Global Burden of Disease Study 2021 (GBD 2021) to analyze the current status and trends of COPD burden in China, aiming to provide epidemiological data to support prevention, early intervention, and policy formulation related to COPD. Methods: This study employs the GBD 2021 database and utilizes various statistical methods, including estimated annual percentage change, Joinpoint regression analysis, decomposition analysis, predictive analysis, and risk factor attribution, to conduct a stratified analysis of the burden of COPD in China by sex, age, and time. Results: Between 1990 and 2021, the age-standardized rate (ASR) of COPD in China showed a significant decline, with projections indicating that this trend will continue. However, the rate of decline has slowed in recent years, and the absolute number of COPD patients continues to rise. In 2021, the age-standardized incidence rate (ASIR) was 215.62 per 100,000, the age-standardized prevalence rate (ASPR) was 2,499.35 per 100,000, the age-standardized mortality rate (ASMR) was 73.23 per 100,000, and the age-standardized disability-adjusted life years (ASDR) was 1,227.66 per 100,000. The decline was more pronounced in females than in males, with females experiencing a lower overall burden. For both sexes, the ASR of COPD increased with age; prior to age 60, rates were similar, but after age 60, males exhibited higher ASMR and ASDR than females. Population aging is identified as the primary driver of the increasing burden of COPD, while epidemiological changes contribute to its reduction. Smoking remains the leading risk factor for mortality, with eight related risk factors identified. Conclusion: While the ASR of COPD in China has significantly improved, the absolute burden continues to escalate, with notable differences by age and sex. Future efforts should focus on enhancing preventive measures for major risk factors and implementing early screening for high-risk populations to promote early diagnosis and treatment strategies, thereby alleviating the disease burden.

Indexed as

Chinachronic obstructive pulmonary diseaseDALYsincidencemortalityprevalence

Identifiers

PMID41169432
PMCPMC12568032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.